Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Immvira Bioscience Files for Hong Kong IPO to Advance Novel Oncolytic Immunotherapy and Engineered Exosome Pipeline

Fineline Cube Jul 17, 2026
Company Deals

Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression

Fineline Cube Jul 17, 2026
Company Deals

Jasper Therapeutics Completes Acquisition of Kira Pharmaceuticals in All-Stock Transaction, Secures $132M Private Placement for Complement Therapies Pipeline

Fineline Cube Jul 17, 2026
Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Fineline Cube Jul 16, 2026
Company Deals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

Fineline Cube Jul 16, 2026
Policy / Regulatory

China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs

Fineline Cube Jul 16, 2026
Company Drug

CSPC Pharmaceutical Launches Phase III Trial of B7-H3-Targeting ADC SYS 6043 for Platinum-Resistant Ovarian Cancer

Fineline Cube Jul 17, 2026
Company Drug

CSPC Pharmaceutical Launches Phase II Trial of Albumin-Bound Sirolimus for Rare Vascular Tumor Epithelioid Hemangioendothelioma

Fineline Cube Jul 17, 2026
Company Deals

Mirxes and NAGAWA Launch Free Gastric Cancer Screening Project in Japan

Fineline Cube Jul 28, 2025

Singapore-based Mirxes Group (HKG: 2629) announced on July 23, 2025, that it has entered into...

Company Drug

Ascletis Pharma Doses First Patients in U.S. Phase 2a Trial for Monthly GLP-1 Agonist ASC30

Fineline Cube Jul 28, 2025

China-based Ascletis Pharma Inc. (HKG: 1672) announced that the first participants with obesity or overweight...

Company Drug

Sobi North America’s Doptelet Approved by FDA for Pediatric ITP Treatment

Fineline Cube Jul 28, 2025

Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi), announced today...

Company Deals

Hengrui and GSK Enter Global Licensing Pact for PDE3/4 Inhibitor HRS-9821

Fineline Cube Jul 28, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced on July 28, 2025, that it...

Company Drug

Pfizer and BioNTech’s LP.8.1 COVID-19 Vaccine Gets EMA CHMP Nod

Fineline Cube Jul 28, 2025

US giant Pfizer Inc., (NYSE: PFE) and Germany-based BioNTech SE (NASDAQ: BNTX) announced today that...

Company Medical Device

Sansure Biotech’s Gene Polymorphism Detection Kits Receive NMPA Class III IVD Certification

Fineline Cube Jul 28, 2025

China-based Sansure Biotech Inc. (SHA: 688289) announced on July 28, 2025, that it has received...

Policy / Regulatory

NMPA Approves Ambroxol Hydrochloride Oral Drops for Over-the-Counter Sale

Fineline Cube Jul 28, 2025

China’s National Medical Products Administration (NMPA) has approved the switch of ambroxol hydrochloride oral drops...

Company Drug

Biogen’s Zurzuvae Receives Positive CHMP Opinion for Postpartum Depression Treatment

Fineline Cube Jul 28, 2025

US-based Biogen (NASDAQ: BIIB) announced that the Committee for Medicinal Products for Human Use (CHMP)...

Others

GSK’s Blenrep Approved in EU for Relapsed or Refractory Multiple Myeloma

Fineline Cube Jul 28, 2025

UK-based GlaxoSmithKline (GSK; NYSE: GSK) announced today that Blenrep has received European Union (EU) approval...

Company Drug

Sanofi’s Sarclisa Approved in EU for Newly Diagnosed Multiple Myeloma

Fineline Cube Jul 28, 2025

France-based Sanofi (NASDAQ: SNY) announced that the European Commission has approved its anti-CD38 monoclonal antibody...

Company Deals

Velavigo Closes $60 Million Pre-A+ Financing Round to Advance Global Clinical Trials

Fineline Cube Jul 28, 2025

Velavigo, a Shanghai-based pharmaceutical startup, has reportedly secured USD 60 million in a Pre-A+ financing...

Company Deals

Matchpoint Therapeutics Partners with Novartis to Develop Oral Covalent Inhibitors for Inflammatory Diseases

Fineline Cube Jul 28, 2025

Matchpoint Therapeutics, a privately held biotechnology company based in Watertown, Massachusetts, announced an exclusive option...

Company Drug

SinoCellTech’s SCT640C Injection Receives NMPA Approval for RA Clinical Trials

Fineline Cube Jul 25, 2025

China-based SinoCellTech Group Ltd (SHA: 688520) announced today that its self-developed product, SCT640C injection, has...

Company Drug

Hengrui Pharmaceuticals’ HRS8179 and HRS-1893 Receive NMPA Clinical Trial Approval

Fineline Cube Jul 25, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced today that it has received clinical...

Company Medical Device

Cryofocus Medtech’s Asthma Cryoablation System Granted FDA Breakthrough Device Designation

Fineline Cube Jul 25, 2025

China-based Cryofocus Medtech (Shanghai) Co., Ltd. (HKG: 6922) announced today that its self-developed asthma cryoablation...

Company Deals

3Sbio and Pfizer Finalize Licensing Agreement for PD-1/VEGF Bispecific Antibody SSGJ-707

Fineline Cube Jul 25, 2025

China-based 3Sbio Inc. (HKG: 1530) announced today that its global licensing agreement with Pfizer Inc.,...

Company

Roche AG Reports 7% Sales Growth in H1 2025, Driven by Pharmaceuticals Expansion

Fineline Cube Jul 25, 2025

Swiss giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced its H1 2025 financial results, reporting...

Company Drug

GenFleet Therapeutics Announces Fast Track Designation for GFH375/VS-7375 in Pancreatic Cancer

Fineline Cube Jul 25, 2025

China-based GenFleet Therapeutics announced on July 25, 2025, that its oral KRAS G12D inhibitor, GFH375/VS-7375,...

Company Deals

Leads Biolabs Lists on Hong Kong Stock Exchange in $189 Million IPO

Fineline Cube Jul 25, 2025

China-based Leads Biolabs (HKG: 9887) officially listed on the Main Board of the Hong Kong...

Company Deals

Everest Medicines Completes HK$1.57 Billion Share Placement to Advance R&D and Commercialization

Fineline Cube Jul 25, 2025

China-based Everest Medicines (HKG: 1952) announced today the completion of a share placement of 22,561,000...

Posts pagination

1 … 153 154 155 … 696

Recent updates

  • CSPC Pharmaceutical Launches Phase III Trial of B7-H3-Targeting ADC SYS 6043 for Platinum-Resistant Ovarian Cancer
  • CSPC Pharmaceutical Launches Phase II Trial of Albumin-Bound Sirolimus for Rare Vascular Tumor Epithelioid Hemangioendothelioma
  • Immvira Bioscience Files for Hong Kong IPO to Advance Novel Oncolytic Immunotherapy and Engineered Exosome Pipeline
  • Abbott Reports Strong Q2 2026 Results with 12.2% Revenue Growth Driven by Diagnostics Surge and Medical Device Innovation
  • Hengrui’s HRS9531 Dual GIPR/GLP-1R Agonist Advances to Phase III for Obesity with Knee Osteoarthritis, Expanding Metabolic Disease Portfolio
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CSPC Pharmaceutical Launches Phase III Trial of B7-H3-Targeting ADC SYS 6043 for Platinum-Resistant Ovarian Cancer

Company Drug

CSPC Pharmaceutical Launches Phase II Trial of Albumin-Bound Sirolimus for Rare Vascular Tumor Epithelioid Hemangioendothelioma

Company Deals

Immvira Bioscience Files for Hong Kong IPO to Advance Novel Oncolytic Immunotherapy and Engineered Exosome Pipeline

Company

Abbott Reports Strong Q2 2026 Results with 12.2% Revenue Growth Driven by Diagnostics Surge and Medical Device Innovation

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.